carmofur has been researched along with Leukemia L 1210 in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively." | 1.31 | Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine. ( Higashigawa, M; Kagawa, Y; Kakito, H; Kawasaki, H; Kojima, M; Ohkubo, T; Ooi, A; Sakurai, M, 2001) |
| "This study attempted to develop sustained release implantable dosage forms based on PHYCON 6600, a new silicone gel." | 1.28 | Application of PHYCON 6600 to achieve sustained release of an antitumor drug (carmofur). ( Azuma, T; Imasaka, K; Nagai, T; Ueda, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshi, A | 1 |
| Yoshida, M | 1 |
| Inomata, M | 1 |
| Iigo, M | 1 |
| Ando, N | 1 |
| Kuretani, K | 1 |
| Ooi, A | 1 |
| Ohkubo, T | 1 |
| Higashigawa, M | 1 |
| Kawasaki, H | 1 |
| Kakito, H | 1 |
| Kagawa, Y | 1 |
| Kojima, M | 1 |
| Sakurai, M | 1 |
| Imasaka, K | 1 |
| Ueda, H | 1 |
| Azuma, T | 1 |
| Nagai, T | 1 |
| Kato, T | 1 |
| Ota, K | 1 |
4 other studies available for carmofur and Leukemia L 1210
| Article | Year |
|---|---|
Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Fluorouracil; Leukemia L1210; Leukemia L5178; Male; | 1980 |
Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Drug Combinations; F | 2001 |
Application of PHYCON 6600 to achieve sustained release of an antitumor drug (carmofur).
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Drug Implants; Excipients; Fluorouracil | 1989 |
[Effects of derivatives of Ara-C, 5-fluorouracil and nitrosourea against intracerebral implanted L1210 leukemia].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1987 |